A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Clinically Detected Lymph Node Metastases

Trial Profile

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Clinically Detected Lymph Node Metastases

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Cancer metastases; Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ADAM
  • Most Recent Events

    • 28 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 14 Nov 2017 Planned initiation date changed from 30 Oct 2017 to 30 Dec 2017.
    • 25 Sep 2017 Planned initiation date changed from 30 Sep 2017 to 30 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top